At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 162 enrolled
Drug / intervention
varenicline (Champix/Chantix) +1 moredrug
Likely dose
varenicline (Champix/Chantix) 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?
In Brief
A Phase 2 clinical trial evaluating varenicline (Champix/Chantix) and placebo for varenicline for Alcohol Dependence. Completed, enrolled 162 participants across 3 sites.
Detailed Summary
The aim of the present clinical trial is to investigate whether 14 weeks of treatment with a prescription medication for smoking cessation (European trade name: Champix(R); US trade name: Chantix(R)), can reduce alcohol consumption in alcohol dependent individuals.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Dependence
CountriesSweden
CollaboratorsKarolinska University Hospital, Malmö University
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2009
Enrollment StartMar 2009
Primary CompletionAug 2010
Study CompletionJan 2011
TodayJul 2026
First PostedFeb 19, 2009
Enrollment StartMar 1, 2009
Primary CompletionAug 1, 2010
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.4 years ago
Interventions
varenicline (Champix/Chantix)drug
14 weeks of per oral tablet treatment in an escalating dosing regimen (0.5 mg - 1.0 mg/day; 1 - 2 tablets/day).
placebo for vareniclinedrug
14 weeks of per oral tablet treatment in an escalating dosing regimen (1 - 2 tablets/day)